Hemic and Lymphatic Diseases: News and Research on Blood Protein Disorders

MeSH tree: C15.378.147

New therapeutic target expands options for multiple myeloma

In a phase 1 clinical trial, treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma, many of whom had already undergone multiple other cancer treatments, ...

Blood cancer marker could help identify patients at high risk

Australian researchers have found a new biomarker for multiple myeloma that could help doctors rapidly identify patients at greatest risk of poor outcomes, enabling more personalized and effective treatments. Multiple myeloma ...

page 1 from 23